Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine
Objectives: In this prospective study, SARS-CoV−2 spike protein specific total immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster vaccination in individuals previously administered with two doses of BBIBP-CorV vaccine in comparison to immunized participants with three d...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/3/556 |
| _version_ | 1827760206867595264 |
|---|---|
| author | Éva Rákóczi Gusztáv Magócs Sára Kovács Béla Nagy Gabriella Szűcs Zoltán Szekanecz |
| author_facet | Éva Rákóczi Gusztáv Magócs Sára Kovács Béla Nagy Gabriella Szűcs Zoltán Szekanecz |
| author_sort | Éva Rákóczi |
| collection | DOAJ |
| description | Objectives: In this prospective study, SARS-CoV−2 spike protein specific total immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster vaccination in individuals previously administered with two doses of BBIBP-CorV vaccine in comparison to immunized participants with three doses of BNT162 b2 vaccination. Methods: Sixty-one Caucasian volunteers (39 females, 22 males) vaccinated by BBIBP-CorV were included (mean age: 63.9 years). Sixty-one patients (41 females, 20 males) as controls were vaccinated with BNT162b2 (mean age: 59.9 years). Both groups received the third booster BNT162b2 vaccine. Total anti-SARS-CoV−2 S1-RBD Ig levels were measured by an immunoassay (Roche Diagnostics) and their calculated ratios after/before booster dose were compared between the two groups. Results: At baseline, significantly lower anti-SARS-CoV−2 S1-RBD total antibody levels were determined after initial immunization by two doses of inactivated BBIBP-CorV compared to BNT62b2 mRNA vaccine (p < 0.001). After BNT162b2 boosters, similarly high total Ig levels were detected in both the heterologous (27,195 [15,604–42,754] BAU/mL, <i>p</i> < 0.001) and the homologous booster cohort (24,492 [13,779−42,671] BAU/mL, <i>p</i> < 0.001) compared to baseline. Hence, the ratio of after/before total Ig levels was significantly higher with heterologous vs homologous immunization (<i>p</i> < 0.001). Conclusion: To address the concept that basic BBIBP-CorV vaccination is not as effective as BNT162b, we analyzed the effect of heterologous vaccination with BNT162b2. Our results suggest that BNT162b2 can successfully boost the effects of two-dose BBIBP-CorV vaccination. |
| first_indexed | 2024-03-11T09:48:16Z |
| format | Article |
| id | doaj.art-9aee2aa6088f4fc0a196a3603e96e511 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T09:48:16Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-9aee2aa6088f4fc0a196a3603e96e5112023-11-16T16:26:33ZengMDPI AGDiagnostics2075-44182023-02-0113355610.3390/diagnostics13030556Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster VaccineÉva Rákóczi0Gusztáv Magócs1Sára Kovács2Béla Nagy3Gabriella Szűcs4Zoltán Szekanecz5Department of Rheumatology, Faculty of Medicine, University of Debrecen, 4023 Debrecen, HungaryGeneral Practitioner Service, 4283 Létavértes, HungaryDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4023 Debrecen, HungaryDepartment of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4023 Debrecen, HungaryDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4023 Debrecen, HungaryDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4023 Debrecen, HungaryObjectives: In this prospective study, SARS-CoV−2 spike protein specific total immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster vaccination in individuals previously administered with two doses of BBIBP-CorV vaccine in comparison to immunized participants with three doses of BNT162 b2 vaccination. Methods: Sixty-one Caucasian volunteers (39 females, 22 males) vaccinated by BBIBP-CorV were included (mean age: 63.9 years). Sixty-one patients (41 females, 20 males) as controls were vaccinated with BNT162b2 (mean age: 59.9 years). Both groups received the third booster BNT162b2 vaccine. Total anti-SARS-CoV−2 S1-RBD Ig levels were measured by an immunoassay (Roche Diagnostics) and their calculated ratios after/before booster dose were compared between the two groups. Results: At baseline, significantly lower anti-SARS-CoV−2 S1-RBD total antibody levels were determined after initial immunization by two doses of inactivated BBIBP-CorV compared to BNT62b2 mRNA vaccine (p < 0.001). After BNT162b2 boosters, similarly high total Ig levels were detected in both the heterologous (27,195 [15,604–42,754] BAU/mL, <i>p</i> < 0.001) and the homologous booster cohort (24,492 [13,779−42,671] BAU/mL, <i>p</i> < 0.001) compared to baseline. Hence, the ratio of after/before total Ig levels was significantly higher with heterologous vs homologous immunization (<i>p</i> < 0.001). Conclusion: To address the concept that basic BBIBP-CorV vaccination is not as effective as BNT162b, we analyzed the effect of heterologous vaccination with BNT162b2. Our results suggest that BNT162b2 can successfully boost the effects of two-dose BBIBP-CorV vaccination.https://www.mdpi.com/2075-4418/13/3/556COVID−19BBIBP-CorVBNT62b2boostervaccine |
| spellingShingle | Éva Rákóczi Gusztáv Magócs Sára Kovács Béla Nagy Gabriella Szűcs Zoltán Szekanecz Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine Diagnostics COVID−19 BBIBP-CorV BNT62b2 booster vaccine |
| title | Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine |
| title_full | Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine |
| title_fullStr | Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine |
| title_full_unstemmed | Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine |
| title_short | Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine |
| title_sort | evaluation of the efficacy of bbibp corv inactivated vaccine combined with bnt62b2 mrna booster vaccine |
| topic | COVID−19 BBIBP-CorV BNT62b2 booster vaccine |
| url | https://www.mdpi.com/2075-4418/13/3/556 |
| work_keys_str_mv | AT evarakoczi evaluationoftheefficacyofbbibpcorvinactivatedvaccinecombinedwithbnt62b2mrnaboostervaccine AT gusztavmagocs evaluationoftheefficacyofbbibpcorvinactivatedvaccinecombinedwithbnt62b2mrnaboostervaccine AT sarakovacs evaluationoftheefficacyofbbibpcorvinactivatedvaccinecombinedwithbnt62b2mrnaboostervaccine AT belanagy evaluationoftheefficacyofbbibpcorvinactivatedvaccinecombinedwithbnt62b2mrnaboostervaccine AT gabriellaszucs evaluationoftheefficacyofbbibpcorvinactivatedvaccinecombinedwithbnt62b2mrnaboostervaccine AT zoltanszekanecz evaluationoftheefficacyofbbibpcorvinactivatedvaccinecombinedwithbnt62b2mrnaboostervaccine |